<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>InGel Therapeutics — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>

<header class="site-header">
  <h1>Prospect Detail</h1>
</header>

<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>

  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Digital Health</span>
    <h1>39. InGel Therapeutics</h1>
    <p class="meta">Vision Restoration via Stem Cells</p>
  </div>

  <div class="caution-box">
    <strong>Sourcing Note:</strong> InGel Therapeutics was a President's Innovation Challenge 2023 finalist, affiliated with Harvard Innovation Labs. Use with caution per assignment sourcing rules.
  </div>

  <div class="section">
    <h3>1. Startup Name</h3>
    <p><strong>InGel Therapeutics</strong></p>
  </div>

  <div class="section">
    <h3>2. Founder Contact</h3>
    <p><strong>HBS/HMS Team</strong></p>
    <p>Harvard Business School / Harvard Medical School</p>
  </div>

  <div class="section">
    <h3>3. Product Overview</h3>
    <p>InGel Therapeutics leverages stem cell and tissue engineering technology to rescue and restore vision for blind patients. The company is developing regenerative medicine approaches to treat degenerative eye diseases that currently have no cure.</p>
  </div>

  <div class="section">
    <h3>4. Funding Stage</h3>
    <p><strong>Early Stage</strong> — President's Innovation Challenge 2023 finalist.</p>
  </div>

  <div class="section">
    <h3>5. How I Found the Company</h3>
    <p>Discovered through Harvard President's Innovation Challenge 2023 finalist announcements in the health track.</p>
  </div>

  <div class="strengths-weaknesses">
    <div class="section">
      <h3>Strengths</h3>
      <ul>
        <li><strong>Massive unmet need:</strong> Millions suffer from vision loss with limited treatment options.</li>
        <li><strong>Harvard research backing:</strong> Access to world-class stem cell and ophthalmology research infrastructure.</li>
      </ul>
    </div>
    <div class="section">
      <h3>Weaknesses</h3>
      <ul>
        <li><strong>Long development timeline:</strong> Regenerative medicine therapies require extensive clinical trials and FDA approval.</li>
        <li><strong>Capital intensive:</strong> Biotech development requires significant funding before revenue generation.</li>
      </ul>
    </div>
  </div>

  <div class="section">
    <h3>7. Five Questions for the Team</h3>
    <ol class="questions-list">
      <li>What specific eye conditions are you targeting and what is the patient population size?</li>
      <li>What stage of preclinical development are you in and what are your FDA pathway plans?</li>
      <li>What IP do you have around your stem cell and tissue engineering approach?</li>
      <li>How much capital do you estimate needing to reach clinical trials?</li>
      <li>Who are the key scientific advisors and what is their track record in ophthalmology?</li>
    </ol>
  </div>

  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>

</body>
</html>
